Published in Sci Transl Med on June 16, 2010
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01
Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J (2011) 2.17
Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet (2011) 2.13
Prospects for treatment of latent HIV. Clin Pharmacol Ther (2012) 1.91
RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol (2010) 1.80
Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog (2011) 1.50
HIV-1 transcription and latency: an update. Retrovirology (2013) 1.49
Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. Proc Natl Acad Sci U S A (2014) 1.49
Researchers knock down gene to stop HIV in its tracks. Nat Med (2010) 1.46
New generation humanized mice for virus research: comparative aspects and future prospects. Virology (2013) 1.38
Developing strategies for HIV-1 eradication. Trends Immunol (2012) 1.38
Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol (2012) 1.36
Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr (2013) 1.34
Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell (2012) 1.33
International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med (2016) 1.29
Can HIV be cured with stem cell therapy? Nat Biotechnol (2010) 1.27
Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years. Clin Exp Immunol (2011) 1.23
Chemokine receptor 5 knockout strategies. Curr Opin HIV AIDS (2011) 1.22
Finding a cure for HIV: will it ever be achievable? J Int AIDS Soc (2011) 1.18
CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS One (2014) 1.16
Hematopoietic cell transplantation with cord blood for cure of HIV infections. Biol Blood Marrow Transplant (2012) 1.13
Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. J Virol (2012) 1.12
Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood (2012) 1.11
Hematopoietic stem cell engineering at a crossroads. Blood (2011) 1.10
Tiling genomes of pathogenic viruses identifies potent antiviral shRNAs and reveals a role for secondary structure in shRNA efficacy. Proc Natl Acad Sci U S A (2012) 1.09
Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice. PLoS Pathog (2013) 1.08
Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med (2012) 1.07
Replication-competent lentivirus analysis of clinical grade vector products. Mol Ther (2010) 1.04
Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells. Mol Ther (2010) 1.03
Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells. Blood (2014) 1.03
HIV develops indirect cross-resistance to combinatorial RNAi targeting two distinct and spatially distant sites. Mol Ther (2012) 1.01
Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice. PLoS One (2012) 1.01
The dose can make the poison: lessons learned from adverse in vivo toxicities caused by RNAi overexpression. Silence (2011) 1.00
Novel approaches to inhibit HIV entry. Viruses (2012) 1.00
Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis (2013) 0.99
Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. PLoS One (2010) 0.99
HIV/AIDS eradication. Bioorg Med Chem Lett (2013) 0.98
Evolutionary analysis of human immunodeficiency virus type 1 therapies based on conditionally replicating vectors. PLoS Comput Biol (2012) 0.97
GPI-anchored single chain Fv--an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike. Retrovirology (2010) 0.97
AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy. Mol Ther (2011) 0.97
Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication. Mol Med (2012) 0.96
Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure? Mol Ther (2013) 0.95
Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep (2015) 0.94
Stem cell-based anti-HIV gene therapy. Virology (2011) 0.94
Antiviral RNAi: translating science towards therapeutic success. Pharm Res (2011) 0.94
Characterization of an HIV-targeted transcriptional gene-silencing RNA in primary cells. Hum Gene Ther (2012) 0.93
Preclinical in vivo evaluation of the safety of a multi-shRNA-based gene therapy against HIV-1. Mol Ther Nucleic Acids (2013) 0.93
Creating genetic resistance to HIV. Curr Opin Immunol (2012) 0.93
Current progress in the development of RNAi-based therapeutics for HIV-1. Gene Ther (2011) 0.93
Gene regulation by non-coding RNAs. Crit Rev Biochem Mol Biol (2013) 0.92
VIRsiRNAdb: a curated database of experimentally validated viral siRNA/shRNA. Nucleic Acids Res (2011) 0.92
Ex vivo gene therapy for HIV-1 treatment. Hum Mol Genet (2011) 0.92
Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol (2013) 0.92
Development of hematopoietic stem cell based gene therapy for HIV-1 infection: considerations for proof of concept studies and translation to standard medical practice. Viruses (2013) 0.91
HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses (2014) 0.89
Excision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinase. PLoS One (2012) 0.89
AIDS-Related Non-Hodgkin's Lymphoma in the Era of Highly Active Antiretroviral Therapy. Adv Hematol (2012) 0.89
Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. J Transl Med (2012) 0.88
Center for fetal monkey gene transfer for heart, lung, and blood diseases: an NHLBI resource for the gene therapy community. Hum Gene Ther (2012) 0.88
Practical considerations in gene therapy for HIV cure. Curr HIV/AIDS Rep (2014) 0.88
Lens epithelium-derived growth factor/p75 qualifies as a target for HIV gene therapy in the NSG mouse model. Mol Ther (2012) 0.88
Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1. BioDrugs (2012) 0.87
Aptamer-based therapeutics: new approaches to combat human viral diseases. Pharmaceuticals (Basel) (2013) 0.86
Endogenous MCM7 microRNA cluster as a novel platform to multiplex small interfering and nucleolar RNAs for combinational HIV-1 gene therapy. Hum Gene Ther (2012) 0.86
Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS. Mol Ther Methods Clin Dev (2016) 0.85
Optimized lentiviral vectors for HIV gene therapy: multiplexed expression of small RNAs and inclusion of MGMT(P140K) drug resistance gene. Mol Ther (2014) 0.85
Computational models of HIV-1 resistance to gene therapy elucidate therapy design principles. PLoS Comput Biol (2010) 0.85
Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. Mol Ther Methods Clin Dev (2014) 0.85
De-repressing LncRNA-Targeted Genes to Upregulate Gene Expression: Focus on Small Molecule Therapeutics. Mol Ther Nucleic Acids (2014) 0.83
The therapeutic application of CRISPR/Cas9 technologies for HIV. Expert Opin Biol Ther (2015) 0.83
Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors. Acta Naturae (2013) 0.83
Hematopoietic cell transplantation and HIV cure: where we are and what next? Blood (2013) 0.82
Current progress and challenges in HIV gene therapy. Future Virol (2011) 0.82
Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16. J Virol (2011) 0.82
Optimized processing of growth factor mobilized peripheral blood CD34+ products by counterflow centrifugal elutriation. Stem Cells Transl Med (2012) 0.82
RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside. Yale J Biol Med (2011) 0.82
Lentivirus-mediated Gene Transfer in Hematopoietic Stem Cells Is Impaired in SHIV-infected, ART-treated Nonhuman Primates. Mol Ther (2015) 0.82
Selection of RNAi-based inhibitors for anti-HIV gene therapy. World J Virol (2012) 0.81
In vivo selection of CD4(+) T cells transduced with a gamma-retroviral vector expressing a single-chain intrabody targeting HIV-1 tat. Hum Gene Ther (2012) 0.81
Combinatorial RNA-based gene therapy for the treatment of HIV/AIDS. Expert Opin Biol Ther (2013) 0.81
Hematopoietic stem cell transplantation for HIV cure. J Clin Invest (2016) 0.81
Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors. Gene Ther (2013) 0.81
CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape. Viruses (2015) 0.81
Antiviral Stratagems Against HIV-1 Using RNA Interference (RNAi) Technology. Evol Bioinform Online (2013) 0.81
RNA interference approaches for treatment of HIV-1 infection. Genome Med (2015) 0.81
Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy. PLoS One (2014) 0.81
Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitor. J Virol (2012) 0.81
Stem-cell-based gene therapy for HIV infection. Viruses (2013) 0.81
Oxygen concentration controls epigenetic effects in models of familial paraganglioma. PLoS One (2015) 0.80
Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice. J Virol (2015) 0.80
Gene therapy strategies for HIV/AIDS: preclinical modeling in humanized mice. Viruses (2013) 0.80
Stem cell-based approaches to treating HIV infection. Curr Opin HIV AIDS (2011) 0.80
Zinc Finger Nucleases: Tailor-made for Gene Therapy. Drugs Future (2012) 0.79
RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope. Mol Ther Methods Clin Dev (2016) 0.79
Production of CGMP-Grade Lentiviral Vectors. Bioprocess Int (2012) 0.79
Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus. World J Virol (2015) 0.79
Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives. Biomed Res Int (2014) 0.79
Bone Marrow Gene Therapy for HIV/AIDS. Viruses (2015) 0.79
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 28.95
A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med (1993) 17.71
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68
Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science (2009) 8.80
The challenge of finding a cure for HIV infection. Science (2009) 8.41
Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis (2006) 3.72
Gene therapy. Intracellular immunization. Nature (1988) 3.60
Genetic therapies against HIV. Nat Biotechnol (2007) 2.50
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med (2009) 2.21
Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther (2006) 1.99
Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther (2009) 1.97
Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther (2002) 1.85
Integration site selection by HIV-based vectors in dividing and growth-arrested IMR-90 lung fibroblasts. Mol Ther (2005) 1.85
Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther (2003) 1.82
Safety and efficacy of a lentiviral vector containing three anti-HIV genes--CCR5 ribozyme, tat-rev siRNA, and TAR decoy--in SCID-hu mouse-derived T cells. Mol Ther (2007) 1.63
Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. Mol Ther (2003) 1.46
Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. Proc Natl Acad Sci U S A (1992) 1.45
Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther (2007) 1.44
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood (2004) 1.44
Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther (2004) 1.37
Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. J Virol (1999) 1.37
Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. Gene Ther (2008) 1.32
Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol Ther (2005) 1.28
RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication. J Virol (1997) 1.23
Survival of the fittest: in vivo selection and stem cell gene therapy. Blood (2005) 1.19
Lentivirus vectors expressing short hairpin RNAs against the U3-overlapping region of HIV nef inhibit HIV replication and infectivity in primary macrophages. Blood (2006) 1.09
Cytokines, including stem cell factor alone, enhance lentiviral transduction in nondividing human LTCIC and NOD/SCID repopulating cells. Mol Ther (2003) 1.06
Lentiviruses in gene therapy clinical research. Gene Ther (2002) 1.06
Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. Clin Immunol (2005) 0.99
Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O(6)-methylguanine-DNA methyltransferase(P140K). Gene Ther (2009) 0.96
Human fetal bone marrow early progenitors for T, B, and myeloid cells are found exclusively in the population expressing high levels of CD34. Blood (1994) 0.95
T Lymphocytes transduced with a lentiviral vector expressing F12-Vif are protected from HIV-1 infection in an APOBEC3G-independent manner. Mol Ther (2005) 0.91
Sustained retroviral gene marking and expression in lymphoid and myeloid cells derived from transduced hematopoietic progenitor cells. Gene Ther (1996) 0.90
Development and characterization of a triple combination gene therapy vector inhibiting HIV-1 multiplication. J Gene Med (2008) 0.89
In vivo selective expansion of gene-modified hematopoietic cells in a nonhuman primate model. Gene Ther (2002) 0.86
Production of lentiviruses displaying ''early-acting'' cytokines for selective gene transfer into hematopoietic stem cells. Methods Mol Biol (2008) 0.85
Fusion of Epstein-Barr virus nuclear antigen-1-derived glycine-alanine repeat to trans-dominant HIV-1 Gag increases inhibitory activities and survival of transduced cells in vivo. Hum Gene Ther (2008) 0.85
Expression of HIV-1 integrase in CEM cells inhibits HIV-1 replication. J Gene Med (2004) 0.81
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
High-performance genetically targetable optical neural silencing by light-driven proton pumps. Nature (2010) 8.37
Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol (2002) 8.31
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood (2008) 7.01
Unlocking the potential of the human genome with RNA interference. Nature (2004) 6.70
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol (2004) 5.40
Strategies for silencing human disease using RNA interference. Nat Rev Genet (2007) 5.19
Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat Struct Mol Biol (2006) 4.93
MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A (2007) 4.92
Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res (2007) 4.91
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol (2006) 4.87
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med (2013) 4.49
MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A (2008) 4.16
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res (2006) 4.06
TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol (2009) 4.05
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol (2004) 3.85
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant (2010) 3.79
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood (2002) 3.57
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA (2005) 3.14
RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev (2007) 3.13
RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 2.97
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 2.83
Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat (2009) 2.81
Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther (2008) 2.79
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med (2015) 2.77
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
MicroRNAs in disease and potential therapeutic applications. Mol Ther (2007) 2.73
Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res (2007) 2.62
Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood (2010) 2.61
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood (2004) 2.57
Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res (2004) 2.54
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood (2007) 2.49
Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol (2003) 2.48
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood (2013) 2.39
Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol (2007) 2.34
Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood (2010) 2.34
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood (2003) 2.33
Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning. Nat Genet (2003) 2.31
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther (2007) 2.23
Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J (2011) 2.17
Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation. J Biol Chem (2008) 2.17
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood (2011) 2.15
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood (2009) 2.12
SNPs in human miRNA genes affect biogenesis and function. RNA (2009) 2.08
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med (2013) 2.07
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood (2005) 2.04
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res (2009) 2.02
An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med (2011) 1.93
RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr Biol (2007) 1.91
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant (2013) 1.88
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant (2009) 1.87
Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther (2011) 1.87
Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther (2002) 1.85
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
Hematopoietic stem-cell contribution to ectopic skeletogenesis. J Bone Joint Surg Am (2007) 1.83
Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther (2003) 1.82
Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant (2005) 1.81
Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant (2013) 1.80
RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol (2010) 1.80
Localized expression of small RNA inhibitors in human cells. Mol Ther (2003) 1.78
The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease. J Immunol (2008) 1.75
Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood (2004) 1.75
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant (2008) 1.75
Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res (2007) 1.75
Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood (2011) 1.74
Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood (2004) 1.74
Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc (2006) 1.74
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
Primary anaplastic large-cell lymphoma associated with breast implants. Leuk Lymphoma (2011) 1.68
Short hairpin RNA-directed cytosine (CpG) methylation of the RASSF1A gene promoter in HeLa cells. Mol Ther (2005) 1.67
A family of ductile intermetallic compounds. Nat Mater (2003) 1.66